Barclays PLC Increases Stake in Cryoport, Inc. (NASDAQ:CYRX)

Barclays PLC increased its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 272.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 81,417 shares of the company’s stock after acquiring an additional 59,582 shares during the quarter. Barclays PLC’s holdings in Cryoport were worth $660,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in shares of Cryoport by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 169,155 shares of the company’s stock valued at $1,169,000 after purchasing an additional 19,803 shares in the last quarter. Rhumbline Advisers lifted its holdings in Cryoport by 3.4% during the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock worth $443,000 after buying an additional 2,086 shares during the period. Quest Partners LLC boosted its position in Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after acquiring an additional 10,830 shares in the last quarter. NRI Wealth Management LC purchased a new position in shares of Cryoport in the 2nd quarter valued at $132,000. Finally, Federated Hermes Inc. bought a new position in shares of Cryoport in the 2nd quarter worth $774,000. 92.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the sale, the director now directly owns 59,497 shares of the company’s stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the transaction, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,869 shares of company stock valued at $735,673. Insiders own 10.10% of the company’s stock.

Cryoport Stock Performance

CYRX opened at $7.78 on Thursday. The company has a market cap of $384.57 million, a P/E ratio of -2.30 and a beta of 1.62. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average price is $7.49 and its 200-day moving average price is $7.85. Cryoport, Inc. has a 52-week low of $5.32 and a 52-week high of $20.10.

Wall Street Analysts Forecast Growth

CYRX has been the topic of a number of recent research reports. Roth Mkm dropped their price objective on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. UBS Group raised their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, October 18th. Finally, Guggenheim started coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Cryoport currently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.